(R)-N-[5-[2-iodo-1-[(triethylsilyl)-oxy]ethyl]-2-(phenylmethoxy)phenyl]methanesulfonamide | 246262-39-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-N-[5-[2-iodo-1-[(triethylsilyl)-oxy]ethyl]-2-(phenylmethoxy)phenyl]methanesulfonamide
• 英文别名: N-(2-(Benzyloxy)-5-{(1R)-2-iodo-1-[(triethylsilyl)oxy]ethyl}phenyl)methanesulfonamide；N-[2-benzyloxy-5-((1R)-2-iodo-1-triethylsilanyloxy-ethyl)-phenyl]-methanesulfonamide；(R)-N-[2-benzyloxy-5-[2-iodo-1-(triethylsilyloxy)-ethyl]phenyl]methanesulfonamide；(R)-N-[5-[2-iodo-1-[(triethylsilyl)oxy]ethyl]-2-(phenylmethoxy)phenyl]methanesulfonamide；N-{2-benzyloxy-5-(2-iodo-(1R)-1-[(triethylsilyl)oxy]-ethyl)-phenyl}-methanesulfonamide；N-[2-benzyloxy-5-[(1R)-2-iodo-1-(triethylsilyloxy)-ethyl]phenyl]methanesulfonamide；(R)-N-[2-benzyloxy-5-(2-iodo-1-triethylsilyloxyethyl)phenyl]methanesulfonamide；N-[5-[(1R)-2-iodo-1-triethylsilyloxyethyl]-2-phenylmethoxyphenyl]methanesulfonamide
• CAS: 246262-39-5
• 化学式: C₂₂H₃₂INO₄SSi
• 分子量: 561.556
• InChiKey: PWLJYZYRJYCQFS-QFIPXVFZSA-N

物化性质

• 沸点：
  568.0±60.0 °C(Predicted)
• 密度：
  1.375±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.14
• 重原子数：
  30
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  73
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-N-[5-[2-iodo-1-[(triethylsilyl)-oxy]ethyl]-2-(phenylmethoxy)phenyl]methanesulfonamide 在 palladium on activated charcoal 氟化铵 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 N-(5-((R)-2-((R)-1-(3,4-dimethoxyphenyl)-2-phenylethylamino)-1-hydroxyethyl)-2-hydroxyphenyl)methanesulfonamide
  参考文献：
  名称：

  Beta 3 agonists. Part 1: evolution from inception to BMS-194449

  摘要：

  Screening of the BMS collection identified 4-hydroxy-3-methylsulfonanilidoethanolamines as full beta 3 agonists. Substitution of the ethanolamine nitrogen with a benzyl group bearing a para hydrogen bond acceptor promoted beta (3) selectivity. SAR elucidation established that highly selective beta (3) agonists were generated upon substitution of C-alpha with either benzyl to form (R)-1,2-diarylethylamines or with aryl to generate 1,1-diarylmethylamines. This latter subset yielded a clinical candidate, BMS-194449 (35).(1) (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00628-x
• 作为产物：
  描述：

  (R)-N-[5-(2-溴-1-羟乙基)-2-(苯基甲氧基)苯基]甲磺酰胺 在 4-二甲氨基吡啶 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 生成 (R)-N-[5-[2-iodo-1-[(triethylsilyl)-oxy]ethyl]-2-(phenylmethoxy)phenyl]methanesulfonamide
  参考文献：
  名称：

  Beta 3 agonists. Part 1: evolution from inception to BMS-194449

  摘要：

  Screening of the BMS collection identified 4-hydroxy-3-methylsulfonanilidoethanolamines as full beta 3 agonists. Substitution of the ethanolamine nitrogen with a benzyl group bearing a para hydrogen bond acceptor promoted beta (3) selectivity. SAR elucidation established that highly selective beta (3) agonists were generated upon substitution of C-alpha with either benzyl to form (R)-1,2-diarylethylamines or with aryl to generate 1,1-diarylmethylamines. This latter subset yielded a clinical candidate, BMS-194449 (35).(1) (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00628-x

文献信息

• Catecholamine surrogates useful as .beta..sub.3 agonists
  申请人：Bristol-Myers Squibb Company

  公开号：US05776983A1

  公开（公告）日：1998-07-07

  Compounds of the formula ##STR1## or pharmaceutically acceptable salts thereof wherein: A is a bond, --(CH.sub.2).sub.n -- or --CH(B)--, where n is an integer of 1 to 3 and B is --CN, --CON(R.sup.9)R.sup.9' or --CO.sub.2 R.sup.7 ; R.sup.1 is lower alkyl, aryl or arylalkyl; R.sup.2 is hydrogen, hydroxy, alkoxy, --CH.sub.2 OH, cyano, --C(O)OR.sup.7, --CO.sub.2 H, --CONH.sub.2, tetrazole, --CH.sub.2 NH.sub.2 or halogen; ##STR2## R.sup.3 is hydrogen, alkyl, heterocycle or R.sup.4 is hydrogen, alkyl or B; R.sup.5, R.sup.5', R.sup.8, R.sup.8' or R.sup.8" are independently hydrogen, alkoxy, lower alkyl, halogen, --OH, --CN, --(CH.sub.2).sub.n NR.sup.6 COR.sup.7, --CON(R.sup.6)R.sup.6', --CON(R.sup.6)OR.sup.6', --CO.sub.2 R.sup.6, --SR.sup.7, --SOR.sup.7, --SO.sub.2 R.sup.7, --N(R.sup.6)SO.sub.2 R.sup.1, --N(R.sup.6)R.sup.6', --NR.sup.6 COR.sup.7, --OCH.sub.2 CON(R.sup.6)R.sup.6', --OCH.sub.2 CO.sub.2 R.sup.7 or aryl; or R.sup.5 and R.sup.5' or R.sup.8 and R.sup.8' may together with the carbon atoms to which they are attached form an aryl or heterocycle; R.sup.6 and R.sup.6' are independently hydrogen or lower alkyl; and R.sup.7 is lower alkyl; R.sup.9 is hydrogen, lower alkyl, alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl; or R.sup.9 and R.sup.9' may together with the nitrogen atom to which they are attached form a heterocycle; with the proviso that when A is a bond or --(CH.sub.2).sub.n and R.sup.3 is hydrogen or unsubstituted alkyl, then R.sup.4 is B or substituted alkyl. These compounds are beta.sub.3 adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestinal diseases.

  公式为##STR1##的化合物或其药学上可接受的盐，其中：A是键，--(CH.sub.2).sub.n --或--CH(B)--，其中n是1到3的整数，B是--CN，--CON(R.sup.9)R.sup.9'或--CO.sub.2 R.sup.7；R.sup.1是较低的烷基，芳基或芳基烷基；R.sup.2是氢，羟基，烷氧基，--CH.sub.2 OH，氰基，--C(O)OR.sup.7，--CO.sub.2 H，--CONH.sub.2，四唑基，--CH.sub.2 NH.sub.2或卤素；##STR2## R.sup.3是氢，烷基，杂环或R.sup.4是氢，烷基或B；R.sup.5，R.sup.5'，R.sup.8，R.sup.8'或R.sup.8"独立地是氢，烷氧基，较低烷基，卤素，--OH，--CN，--(CH.sub.2).sub.n NR.sup.6 COR.sup.7，--CON(R.sup.6)R.sup.6'，--CON(R.sup.6)OR.sup.6'，--CO.sub.2 R.sup.6，--SR.sup.7，--SOR.sup.7，--SO.sub.2 R.sup.7，--N(R.sup.6)SO.sub.2 R.sup.1，--N(R.sup.6)R.sup.6'，--NR.sup.6 COR.sup.7，--OCH.sub.2 CON(R.sup.6)R.sup.6'，--OCH.sub.2 CO.sub.2 R.sup.7或芳基；或R.sup.5和R.sup.5'或R.sup.8和R.sup.8'可以与它们连接的碳原子一起形成芳基或杂环；R.sup.6和R.sup.6'独立地是氢或较低烷基；R.sup.7是较低烷基；R.sup.9是氢，较低烷基，烷基，环烷基，芳基烷基，芳基，杂芳基；或R.sup.9和R.sup.9'可以与它们连接的氮原子一起形成杂环；但是当A是键或--(CH.sub.2).sub.n且R.sup.3是氢或未取代烷基时，R.sup.4是B或取代烷基。这些化合物是β.sub.3肾上腺素受体激动剂，因此在糖尿病、肥胖症和胃肠疾病的治疗中很有用。
• INDOLE, INDAZOLE, AND BENZAZOLE DERIVATIVE
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：EP1514869A1

  公开（公告）日：2005-03-16

  The compound of the formula (I): wherein W is a group of the following formula (VIII) binding to any possible position on the Q: Q is, together with W, a group of the formula: -C(M=C(R3A)-N(R3)-, etc.; R3A is H or optionally substituted lower alkyl; R4, R5, R6, and R7 are independently H or optionally substituted lower alkyl; R1 is optionally substituted lower alkyl, etc.; R2 is H, etc.; R3 is H, etc.; Ar is phenyl, etc., or a pharmaceutically acceptable salt thereof, where these compounds exhibiting β3-adrenoceptor-stimulating activity and being useful as a medicament for treatment of obesity, etc.

  公式(I)的化合物： 其中W是以下公式(VIII)的基团，可以与Q的任何可能位置结合： Q与W一起是以下公式的基团：-C(M=C(R3A)-N(R3)-等； R3A是H或可选地取代的低级烷基；R4、R5、R6和R7独立的是H或可选地取代的低级烷基；R1是可选地取代的低级烷基等；R2是H等；R3是H等；Ar是苯基等，或其药物可接受的盐，其中这些化合物具有β3-肾上腺素受体刺激活性，并作为治疗肥胖等的药物有用。
• AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1679304A1

  公开（公告）日：2006-07-12

  The present invention provides compounds represented by general formula (I): a prodrug thereof, or pharmaceutical acceptable salts thereof, wherein R1 is hydrogen or lower alkyl; each of R2 and R3 is independently hydrogen or lower alkyl; each of R4, R5 and R6 is independently hydrogen, halogen, lower alkyl or lower alkoxy; R7 is hydrogen or lower alkyl; R8 is hydrogen, halogen, lower alkyl, lower alkoxy, etc; R9 is -COR10, -A1-COR10, -O-A2-COR10, etc; Ar is optionally substituted phenyl or heteroaryl; and A is a bond, -OCH2-, etc, which exhibit potent and selective β3-adrenoceptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

  本发明提供了由通式（I）表示的化合物： 其前药，或其药用可接受的盐，其中R1是氢或较低的烷基；R2和R3中的每一个独立地是氢或较低的烷基；R4、R5和R6中的每一个独立地是氢、卤素、较低的烷基或较低的烷氧基；R7是氢或较低的烷基；R8是氢、卤素、较低的烷基、较低的烷氧基等；R9是-COR10、-A1-COR10、-O-A2-COR10等；Ar是可选择地取代的苯基或杂环芳基；A是键，-OCH2-等，具有强效和选择性的β3-肾上腺素受体刺激活性。本发明还提供了含有所述化合物的药物组合物，以及其用途。
• Propanolamine derivatives
  申请人：Fujisawa Pharmaceutical Co. Ltd.

  公开号：US20020120148A1

  公开（公告）日：2002-08-29

  This invention relates to new propanolamine derivatives or salts thereof represented by the following formula [I]: 1 Wherein each symbol is as defined in the specification or salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment diseases indicated in the specification to a human being or an animal.

  这项发明涉及新的丙醇胺衍生物或其盐，其化学式如下所示：1其中每个符号如规范中定义，或具有选择性肠道交感神经兴奋作用、抗溃疡、抗胰腺炎、脂解作用、抗尿失禁和抗尿频活性的盐，以及其制备方法、包含相同的药物组合物以及用于预防和/或治疗规范中指示的疾病的方法，适用于人类或动物。
• Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
  申请人：Fujisawa Pharmaceutical Co. Ltd.

  公开号：US20020143034A1

  公开（公告）日：2002-10-03

  A compound of the formula (I): 1 wherein X 1 is bond or —OCH 2 —; X 2 is —(CH 2 ) n —, in which n is 1, 2 or 3; X 3 is bond, —O—, —S—, —OCH 2 —, or —NH—; R 1 is phenyl or pyridyl each of which may have one or two substituent(s) selected from the group consisting of hydroxy, halogen, etc.; R 2 is hydrogen, (lower)alkoxycarbonyl, etc.; R 3 is hydroxy(lower)alkyl; halo(lower)alkyl, etc.; R 4 is aryl or unsaturated heterocyclic group, each of which may have one or two substituent(s) selected from the group consisting of lower alkyl, hydroxy, carbamoyl, halogen, lower alkoxy, etc.; and a salt thereof which is useful as a medicament.

  该化合物的结构式如下：其中X1是化学键或—O —；X2是—(CH2)n—，其中n为1、2或3；X3是化学键，—O—，—S—，—O —或—NH—；R1是苯基或吡啶基，每个基上可能有一个或两个亚基，如羟基、卤素等；R2是氢、（低）烷氧羰基等；R3是羟基（低）烷基、卤代（低）烷基等；R4是芳基或不饱和杂环基，每个基上可能有一个或两个亚基，如低烷基、羟基、氨基甲酰基、卤素、低烷氧基等；以及其盐，可用作药物。